- Email: [email protected]
P.4.031 Cerebrovascular reactivity in dementia of Alzheimer's type assessed by acetazolamide SPECT
S398
I?4. Degenerative
and
stroke patieuts. Our iuvestigatious aud literature data permitted us to conclude that either BN itself or products of its metabolism peuetrate the blood-brain barrier aud reach deep structures of the braiu like dieucephalic area and/or restore metabolism aud normal cortical-subcortical couuectious as well as provide improvement of patieiits’ quality of life. References [l]
[2]
mP4
Santiago L.A., Osato J.A., Mori A. Antioxidant protection of Bionormalizer against post-traumatic epilepsy and ishemia-reperfusion injury. Frontiers of reactive oxygen species in biology and medicine. Ed. K Asada and T. Yoshikawa. Elsevier Science. 1994. P.471472. Zhavoronkova L., Maksakova O., et al. EEG-mapping and clinical effects of Bio-Normalizer of the human brain state in remote period after radiation. Abstracts of XXIInd CINP Congress. Int. J. of Neumpsychopharmacology. 2000.V3. S.1. S382.
030
Pharmacokinetic study of donepezil in healthy young
A. Periclou’, D. Ventura’, W. Abramowitz’ ‘Forest Pharmacokinetics, Jersey R&D, ValDy, Denmark
memantine subjects
and
T. Sherman’, N. Rae’, H. Mengel *, Laboratories, Inc., Department of City, New Jersey, US.A.; 2H. LundDeck,
In the US, currently available treatments for Alzheimer’ s disease (AD) are limited to acetylcholiuesterase (AChE) inhibitors, such as douepezil. However, AChE iuhibitors confer ouly modest benefits, uecessitatiug the developmeut of additioual therapeutic ageuts. Memautiue, a moderate affinity, uncompetitive NMDA receptor amagonist, is approved in Europe for the treatment of AD aud is currently uuder iuvestigatiou in the US for this indication The objective of this study was to determine whether au in vivo pharmacokiuetic iuteractiou exists betweeu memautiue aud douepezil. In au open-label, multiple-dose study, 24 healthy subjects (ages 18-35) received 10 mg memautiue orally 011 Day 1. Followiug a 14-day washout period, subjects received 5 mg douepezil orally ouce daily for 7 days 011 au outpatient basis. Beghmiug Day 22, douepezil dosage was doubled for 22 days, aud the last douepezil dose was coucomitautly administered with 10 mg memautiue 011 Day 43. Assessments included phannacokiuetic, phannacodyuamic (AChE inhibition) aud safety parameters (adverse eveut recording, ECG, vital signs aud clinical laboratory tests). The rate aud extent of memautiue absorptiou was uot significantly altered with daily-dosing of douepezil, uor was the bioavailability of multiple-dose douepezil altered with single-dose memautiue. Percent maximum iuhibitiou of AChE activity by douepezil averaged 77.8% aud was uot statistically differeut upon co-administration of memautiue (8 1.1%). Two patients withdrew due to adverse eveuts while treated with douepezil. Of the 19 subjects who completed the study, single doses of memautiue administered with multiple doses of douepezil were well tolerated. Memautiue aud douepezil did uot interact phannacokiuetically or phannacodyuamically, suggesting that they cau be safely coadministered.
neurological
m P4
031
disorders
Cerebrovascular Alzheimer’s SPECT
type
reactivity assessed
in dementia of by acetazolamide
Y.M. Choi, D.W. Lee. Inje University, Sanggyepaik Neuropsychiatry, Seoul, Republic of Korea
Hospital,
Objective: The purpose of this study was to iuvestigate the abuonnality of cerebrovascular reactivity in patients with dementia of Alheimer’ s type by the acetazolamide braiu SPECT, which has beeu used in the assessment of cerebrovascular disease. Method: Eighteeu patients with dementia of Alheimer’ s type, as diagnosed by the criteria of DSM-IV aud NINCDS-ADRDA, aud teu uonnal comparison subjects were recruited. They were rated by Mini-Meutal Status Examination, Mattis Dementia Rating Scale, aud Hamilton Depression Rating Scale. Aud Acetazolamide braiu SPECT scam of patient group aud control group were analyzed by 3-dimensional volume of iuterest method. Results: The results were as follows. 1) There were 110 significam differences in the values of absolute cerebrovasular reactivity betweeu patients with dementia aud comparison subjects. 2) There were significant differences in the values of cerebrovasular reactivity betweeu two groups. The cerebrovasular reactivity of dementia patients was significantly decreased in the right froutal lobe, aud iucreased in left temporal lobe. compared with comparison subjects (pi.05). Conclusion: These results imply the possible role of the abuonnality of cerebrovasular reactivity in the pathophysiology of dementia of Alzheimer’ s type.
mP4
032
Cognitive
influence
of topiramate
in children
M.J. Rebollo2, P. Corredoira3, F.J. Quiutero Gutierrez de1 Alamo’ R.l. Largo Gomez4, E. Baca GarcIa5, F.J. Quiutero Lumbreras’ ‘Fundacion Jimenez-Diaz, Psychiatry, Madrid, Spain; 21nstituto Neuroconductual, Neuropsychology, Madrid, Spain; 3Clinica Dorctor Quintero, Psychology, Madrid, Spain; 41nstituto Neuroconductual, Psychiatry, Madrid, Spain; ‘Fundacion Jimenez-Diaz, Psychology, Madrid, Spain; 6Alcala Univerity, Medical Psychology, Madrid, Spain Introduction: The arrival of uew autiepileptic drugs (AEDs) in psychopharmacological treatment is gaiuiug attention Topiramate has iucreased its reporters about efficacy 011 impulsivity disorders aud 011 the treatment of bipolar disorders, also during the childhood (1). Good tolerability with fewer side effects is reported, however the poteutial cognitive side effects of this ageut is still controversial (2),(3). Wheu we are taking care of children, there must be a priority: “primum 11011 uocere”. Method: In this project we have studied a children’ s populatiou (n=S) betweeu the ages of 8 aud 12, with diagnosis in the spectrum of the conduct disorder. It was asked for verbal iufonned couseut to the patient aud tutors. We look for the iuflueuce of the Topiramate in the perfonnauce 011 some ueuropsychological examination Each patient was explored 3 times; before treatment, after 1 mouth of treatment aud after 3 mouths of treatment. During this study the doses of Topiramate were iucreased slowly (25mg per week). The exam consist in verbal fluency examinations, atteutiou exams, Global cognitive Perfonnauce aud motor speed (Control Oral Word, Coutiuuos Perfonnauce Test, Trial Making, finger tapping, Stroop colour naming, Wiscousiu Card Sorting Test.). The SPSS program was used for the data mauagemeut.
I?4. Degenerative
and
stroke patieuts. Our iuvestigatious aud literature data permitted us to conclude that either BN itself or products of its metabolism peuetrate the blood-brain barrier aud reach deep structures of the braiu like dieucephalic area and/or restore metabolism aud normal cortical-subcortical couuectious as well as provide improvement of patieiits’ quality of life. References [l]
[2]
mP4
Santiago L.A., Osato J.A., Mori A. Antioxidant protection of Bionormalizer against post-traumatic epilepsy and ishemia-reperfusion injury. Frontiers of reactive oxygen species in biology and medicine. Ed. K Asada and T. Yoshikawa. Elsevier Science. 1994. P.471472. Zhavoronkova L., Maksakova O., et al. EEG-mapping and clinical effects of Bio-Normalizer of the human brain state in remote period after radiation. Abstracts of XXIInd CINP Congress. Int. J. of Neumpsychopharmacology. 2000.V3. S.1. S382.
030
Pharmacokinetic study of donepezil in healthy young
A. Periclou’, D. Ventura’, W. Abramowitz’ ‘Forest Pharmacokinetics, Jersey R&D, ValDy, Denmark
memantine subjects
and
T. Sherman’, N. Rae’, H. Mengel *, Laboratories, Inc., Department of City, New Jersey, US.A.; 2H. LundDeck,
In the US, currently available treatments for Alzheimer’ s disease (AD) are limited to acetylcholiuesterase (AChE) inhibitors, such as douepezil. However, AChE iuhibitors confer ouly modest benefits, uecessitatiug the developmeut of additioual therapeutic ageuts. Memautiue, a moderate affinity, uncompetitive NMDA receptor amagonist, is approved in Europe for the treatment of AD aud is currently uuder iuvestigatiou in the US for this indication The objective of this study was to determine whether au in vivo pharmacokiuetic iuteractiou exists betweeu memautiue aud douepezil. In au open-label, multiple-dose study, 24 healthy subjects (ages 18-35) received 10 mg memautiue orally 011 Day 1. Followiug a 14-day washout period, subjects received 5 mg douepezil orally ouce daily for 7 days 011 au outpatient basis. Beghmiug Day 22, douepezil dosage was doubled for 22 days, aud the last douepezil dose was coucomitautly administered with 10 mg memautiue 011 Day 43. Assessments included phannacokiuetic, phannacodyuamic (AChE inhibition) aud safety parameters (adverse eveut recording, ECG, vital signs aud clinical laboratory tests). The rate aud extent of memautiue absorptiou was uot significantly altered with daily-dosing of douepezil, uor was the bioavailability of multiple-dose douepezil altered with single-dose memautiue. Percent maximum iuhibitiou of AChE activity by douepezil averaged 77.8% aud was uot statistically differeut upon co-administration of memautiue (8 1.1%). Two patients withdrew due to adverse eveuts while treated with douepezil. Of the 19 subjects who completed the study, single doses of memautiue administered with multiple doses of douepezil were well tolerated. Memautiue aud douepezil did uot interact phannacokiuetically or phannacodyuamically, suggesting that they cau be safely coadministered.
neurological
m P4
031
disorders
Cerebrovascular Alzheimer’s SPECT
type
reactivity assessed
in dementia of by acetazolamide
Y.M. Choi, D.W. Lee. Inje University, Sanggyepaik Neuropsychiatry, Seoul, Republic of Korea
Hospital,
Objective: The purpose of this study was to iuvestigate the abuonnality of cerebrovascular reactivity in patients with dementia of Alheimer’ s type by the acetazolamide braiu SPECT, which has beeu used in the assessment of cerebrovascular disease. Method: Eighteeu patients with dementia of Alheimer’ s type, as diagnosed by the criteria of DSM-IV aud NINCDS-ADRDA, aud teu uonnal comparison subjects were recruited. They were rated by Mini-Meutal Status Examination, Mattis Dementia Rating Scale, aud Hamilton Depression Rating Scale. Aud Acetazolamide braiu SPECT scam of patient group aud control group were analyzed by 3-dimensional volume of iuterest method. Results: The results were as follows. 1) There were 110 significam differences in the values of absolute cerebrovasular reactivity betweeu patients with dementia aud comparison subjects. 2) There were significant differences in the values of cerebrovasular reactivity betweeu two groups. The cerebrovasular reactivity of dementia patients was significantly decreased in the right froutal lobe, aud iucreased in left temporal lobe. compared with comparison subjects (pi.05). Conclusion: These results imply the possible role of the abuonnality of cerebrovasular reactivity in the pathophysiology of dementia of Alzheimer’ s type.
mP4
032
Cognitive
influence
of topiramate
in children
M.J. Rebollo2, P. Corredoira3, F.J. Quiutero Gutierrez de1 Alamo’ R.l. Largo Gomez4, E. Baca GarcIa5, F.J. Quiutero Lumbreras’ ‘Fundacion Jimenez-Diaz, Psychiatry, Madrid, Spain; 21nstituto Neuroconductual, Neuropsychology, Madrid, Spain; 3Clinica Dorctor Quintero, Psychology, Madrid, Spain; 41nstituto Neuroconductual, Psychiatry, Madrid, Spain; ‘Fundacion Jimenez-Diaz, Psychology, Madrid, Spain; 6Alcala Univerity, Medical Psychology, Madrid, Spain Introduction: The arrival of uew autiepileptic drugs (AEDs) in psychopharmacological treatment is gaiuiug attention Topiramate has iucreased its reporters about efficacy 011 impulsivity disorders aud 011 the treatment of bipolar disorders, also during the childhood (1). Good tolerability with fewer side effects is reported, however the poteutial cognitive side effects of this ageut is still controversial (2),(3). Wheu we are taking care of children, there must be a priority: “primum 11011 uocere”. Method: In this project we have studied a children’ s populatiou (n=S) betweeu the ages of 8 aud 12, with diagnosis in the spectrum of the conduct disorder. It was asked for verbal iufonned couseut to the patient aud tutors. We look for the iuflueuce of the Topiramate in the perfonnauce 011 some ueuropsychological examination Each patient was explored 3 times; before treatment, after 1 mouth of treatment aud after 3 mouths of treatment. During this study the doses of Topiramate were iucreased slowly (25mg per week). The exam consist in verbal fluency examinations, atteutiou exams, Global cognitive Perfonnauce aud motor speed (Control Oral Word, Coutiuuos Perfonnauce Test, Trial Making, finger tapping, Stroop colour naming, Wiscousiu Card Sorting Test.). The SPSS program was used for the data mauagemeut.